Over 6 million people in the USA have Afib, placing them at an increased risk of stroke.¹

The current standard of care for stroke prevention is chronic oral anticoagulants, which are not well accepted by many patients due to the associated risk of bleeding.

LAAO is emerging as an important minimally invasive alternative to blood thinners for reducing the risk of stroke in patients with non-valvular Afib without increased bleeding risk.